SCHEMBL580270

SCHEMBL580270

O=C(O)c1cc(NCc2c(F)c(F)c(C(F)(F)F)c(F)c2F)ccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
POLB P06746 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 5/20 0.43
GAA P10253 4/20 0.43
TSHR P16473 2/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 1/20 0.43
PPARA Q07869 2/20 0.40
STING1 Q86WV6 1/20 0.40
MEN1 O00255 1/20 0.39
PLA2G1B P04054 1/20 0.39
KMT2A Q03164 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39
TP53 P04637 1/20 0.39
PPARG P37231 1/20 0.38
RORC P51449 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL580229 0.86 PPARA (0.55) KDM4ETDP1MAPTALDH1A1PPARA
SCHEMBL27545640 0.86 GAA (0.42) KDM4ETDP1MAPTALDH1A1GAA
Potassium SCHEMBL29515374 0.85 PPARA (0.54) KDM4ETDP1MAPTALDH1A1PPARA
SCHEMBL581497 0.85 PPARA (0.40) KDM4ETDP1MAPTALDH1A1GAA
SCHEMBL581259 0.85 KDM4C (0.42) KDM4EPOLBTDP1MAPTALDH1A1
SCHEMBL3996747 0.85 PPARA (0.54) KDM4ETDP1MAPTALDH1A1PPARA
SCHEMBL3996092 0.85 PPARA (0.54) KDM4ETDP1MAPTALDH1A1PPARA
SCHEMBL3996778 0.85 PPARA (0.54) KDM4ETDP1MAPTALDH1A1PPARA
SCHEMBL3411474 0.84 AKR1C2 (0.40) KDM4EMAPTALDH1A1GAATSHR
SCHEMBL580364 0.82 DTYMK (0.42) POLBTDP1MAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027076-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT PHARMA CO LTD (KR) 2026-01-29 US claimed
US-12433861-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy GNT PHARMA CO., LTD. (KR) 2025-10-07 US claimed
US-20230390231-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT PHARMA CO., LTD. (KR) 2023-12-07 US claimed
US-11826329-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy GNT PHARMA CO., LTD. (KR) 2023-11-28 US claimed
EP-4117648-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT Pharma Co., Ltd (KR) 2023-01-18 EP claimed
CN-115515573-A Compositions and methods for treating reperfusion injury or bleeding following recanalization GNT制药有限公司 2022-12-23 CN claimed
WO-2021181159-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT PHARMA CO., LTD. (KR) 2021-09-16 WO claimed
US-20210283080-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY GNT PHARMA CO., LTD. (KR) 2021-09-16 US claimed
EP-2417972-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES NEUROTECH PHARMACEUTICALS CO LTD (KR) 2017-06-14 EP claimed
EP-1551793-B1 TETRAFLUOROBENZYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES IN CENTRAL NERVOUS SYSTEM CONTAINING THE SAME AMKOR PHARMA INC (US) 2016-01-20 EP claimed
US-20120301551-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2012-11-29 US claimed
US-20120289602-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES ARAONTECH CO., LTD. (KR) 2012-11-15 US claimed
EP-2417972-A2 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES Neurotech Pharmaceuticals Co., Ltd. (KR) 2012-02-15 EP claimed
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-12-27 US claimed
CN-1309703-C Tetrafluorobenzyl derivatives and pharmaceutical composition for treating and preventing acute and chronic neurodegenerative diseases of central nervous system containing the same NEUROTECH CO LTD (KR) 2007-04-11 CN claimed
US-20070049565-A1 Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2007-03-01 US claimed
WO-2006126825-A1 COMPOSITION COMPRISING TETRAFLUOROBENZYL DERIVATIVES OR SALTS OF THEREOF FOR INJECTION CHOONGWAE PHARMA CORPORATION (KR) 2006-11-30 WO claimed
CN-1668576-A Tetrafluorobenzyl derivatives and pharmaceutical composition for treating and preventing acute and chronic neurodegenerative diseases of central nervous system containing the same NEUROTECH CO LTD (KR) 2005-09-14 CN claimed
US-6927303-B2 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH CO., LTD. (KR) 2005-08-09 US claimed
US-20040209957-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same NEUROTECH PHARMACEUTICALS CO., LTD. (KR) 2004-10-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120301551-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING NEURONAL DEATH OR NEUROLOGICAL DYSFUNCTION BCL2, BAX, SMN1; SMN2 KDM4E 3014/4885POLB 3083/4885TDP1 907/4885
US-12433861-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy PLAT, SERPINE1, SERPINC1 KDM4E 4780/4885POLB 1397/4885TDP1 575/4885
US-11826329-B2 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy PLAT, SERPINE1, SERPINC1 KDM4E 4780/4885POLB 1397/4885TDP1 575/4885
US-20230390231-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY PLAT, SERPINE1, SERPINC1 KDM4E 4780/4885POLB 1397/4885TDP1 575/4885
US-20210283080-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY PLAT, SERPINE1, SERPINC1 KDM4E 4780/4885POLB 1397/4885TDP1 575/4885
US-20070298129-A1 Compounds and compositions for treating neuronal death or neurological dysfunction BCL2, BAX, SMN1; SMN2 KDM4E 3014/4885POLB 3083/4885TDP1 907/4885
US-20120289602-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING BURN INJURIES CTSA, CFTR, CPT1A KDM4E 4622/4885POLB 1244/4885TDP1 2495/4885
US-20260027076-A1 COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY FGB, PLAT, CTSH KDM4E 3967/4885POLB 1744/4885TDP1 767/4885
US-20070049565-A1 Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction BAD, MAP1LC3B, XIAP KDM4E 4124/4885POLB 4031/4885TDP1 992/4885
US-20040209957-A1 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same HTT, BDNF, APP KDM4E 3670/4885POLB 3158/4885TDP1 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.